Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
ZS Pharma
July 20, 2017
Looking for value in the deal sweet spot
August 23, 2016
Who’s next after Medivation?
July 21, 2016
For the real Relypsa puzzle look beyond the takeover
May 27, 2016
Astra’s reckless $2.7bn deal hits the regulatory buffers
March 23, 2016
Brilinta and Pascal Soriot lose yet more lustre
December 22, 2015
Happy Christmas for Actelion, but what about the new year?
November 09, 2015
Forehead slaps in order for Astra as data dwarf $2.7bn deal
November 06, 2015
AstraZeneca pips Actelion to ZS Pharma
October 23, 2015
Up is down for Relypsa and Merrimack
September 11, 2015
Hyperkalaemia comes into play for Actelion
January 15, 2015
JPM 2015 – Relypsa awaits lift-off
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
April 16, 2020
Evaluate Vantage COVID-19 Report
Editor's Picks
October 20, 2020
Finding the next Vertex
October 15, 2020
Clinical setback lays bare Vertex’s weakness
October 15, 2020
SITC 2020 – embargo snafu triggers the first movers
October 19, 2020
Biopharma buyouts still pricey
September 30, 2020
More biotechs test the third way to market
